miR-21 Expression in Cancer Cells may Not Predict Resistance to Adjuvant Trastuzumab in Primary Breast Cancer

Trastuzumab is established as standard care for patients with HER2-positive breast cancer both in the adjuvant and metastatic setting. However, 50% of the patients do not respond to the trastuzumab therapy, and therefore new predictive biomarkers are highly warranted. MicroRNAs (miRs) constitute a n...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Nielsen, Boye Schnack, Balslev, Eva, Poulsen, Tim Svenstrup, Nielsen, Dorte, Møller, Trine, Mortensen, Christiane Ehlers, Holmstrøm, Kim, Høgdall, Estrid
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2014
Assuntos:
Oncology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4133651/
https://ncbi.nlm.nih.gov/pubmed/25177545
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2014.00207
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados